Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1013-1022

  Mukozu, Takanori ^a   Nagai, Hidenari ^a   Matsui, Daigo ^a   Kanekawa, Takenori ^a   Sumino, Yasukiyo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinogenesis; HCC; HCV infection; Tumor marker; VEGF

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; PROTEIN AFP L3; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; YOUDEN INDEX;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875891272     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Abelev GI: Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res 28: 1344-1350, 1968.
2. O'Conor GT, Tatarinov YS, Abelev GI and Uriel J: A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 25: 1091-1098, 1970.
3. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR; HALT-C Trial Group: Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol 43: 434-441, 2005.
4. Ezaki T, Yukaya H, Ogawa Y, Chang YC and Nagasue N: Elevation of alpha-fetoprotein level without evidence of recurrence after hepatectomy for hepatocellular carcinoma. Cancer 61: 1880-1883, 1988.
5. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, Satomura S, Matsuura S, Kawai T and Hirai H: A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 53: 5419-5423, 1993.
6. Aoyagi Y, Saitoh A, Suzuki Y, Igarashi K, Oguro M, Yokota T, Mori S, Suda T, Isemura M and Asakura H: Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology 17: 50-52, 1993.
7. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y and Nagataki S: Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 328: 1802-1806, 1993.
8. Fujiyama S, Moroshita T, Hashiguchi O and Sato T: Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 61: 1621-1628, 1988.
9. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS and Furie B: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310: 1427-1431, 1984.
10. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Takada A, Fukumori K, Yano Y, Sumie S, Okuda K, Kumashiro R and Sata M: Diagnostic clues for recurrent hepatocellular carcinoma: Comparison of tumor markers and imaging studies. Eur J Gastroenterol Hepatol 15: 641-648, 2003.
11. Beppu T, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Tanaka J, Yamamoto N, Takei Y, Takaki H, Uraki J, Nakatsuka A, Yamakado K and Takeda K: Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. Int J Mol Med 26: 425-433, 2010.
12. Bruix J: Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL conference. J Hepatotl 35: 421-430, 2001.
13. Omata M: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4: 439-474, 2010.
14. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y and Zhu AX: NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7: 350-391, 2009.
15. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29: 339-64, 2011.
16. Bruix J and Sherman M: Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022, 2011.
17. Semela D and Dufour JF: In: Vascular endothelial growth factor signaling. Signaling Pathways in Liver Disease. Dufour JF, Clavien PA (eds.). Springer-Verlag, Berlin Germany, pp. 91-104, 2005.
18. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S: Increased expression of vascular endotherial growth factor in human hepatocellular carcinoma. J Hepatol 27: 854-861, 1997.
19. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M and Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77, 1998.
20. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Nakatani T, Tsujinoue H and Fukui H: KDR/FLK-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30: 1179-1186, 1999.
21. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K and Kamada T: Expression of permeability factor/vascular endthelial growth factor in human hepatocellular carcinoma. Cancer Res 56: 3004-3009, 1996.
22. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
23. Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY and Tarnawski AS: Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod Pathol 16: 552-557, 2003.
24. Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Doi T, Endo H, Yamashita T and Okada Y: Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33: 376-382, 1998.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M and Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 15113-1520, 1994.
28. Ferroni P, Spila A, D'Alessandro R, Martini F, Iacovone F, Ettorre GM, Vennarecci G, Santoro R, Puoti C and Guadagni F: Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer. Clin Chim Acta 412: 450-454, 2011.
29. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, Kurosawa T, Watanabe M, Kawabata T, Chang W, Li C, Bousse L, Wada HG and Satomura S: Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 388: 306-311, 2009.
30. Kudo M: Imaging diagnosis of hepatocellular carcinoma and remalignant/borderline lesions. Semin Liver Dis 19: 297-309, 1999.
31. Torzilli G, Minagawa M, Takayama T, Inoue K, Hui AM, Kubota K, Ohtomo K and Makuuchi M: Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30: 889-893, 1999.
32. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T and Nagasue N: Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27: 1554-1562, 1998.
33. Plate KH, Breier G, Weich HA and Risau W: Vascular endotherial growth factor is a potential angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
34. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, Dvorak HF and Rosen S: Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 42: 1457-1461, 1992.
35. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J and Imamura M: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23: 455-464, 1996.
36. von Marschall Z, Cramer T, Hocker M, Hocker M, Finkenzeller G, Wiedenmann B and Rosewicz S: Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48: 87-96, 2001.
37. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2: 38-47, 2002.
38. Yeh SH, Chen PJ, Lai MY: Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: Association with elevated alpha-fetoprotein production. Gastroenterology 110: 184-192, 1996.
39. Noda K, Miyoshi E, Gu J, Gao CX, Nakahara S, Kitada T, Honke K, Suzuki K, Yoshihara H, Yoshikawa K, Kawano K, Tonetti M, Kasahara A, Hori M, Hayashi N and Taniguchi N: Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res 63: 6282-6289, 2003.
40. Murata K and Sakamoto A: Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-γ- carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 33: 1149-55, 2008.
41. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y and Sakamoto A: Cytoskeletal changes during epithelial-tofibroblastoid conversion as a crucial mechanism of des-γ- carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 35: 1005-1014, 2009.
42. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K and Yamamoto K: The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106: 867-872, 2006.
43. Kojiro M: Pathological evolution of early hepatocellular carcinoma. Oncology 62: 43-47, 2002.
44. Takayasu K, Shima Y, Muramatsu Y, Goto H, Moriyama N, Yamada T, Makuuchi M, Yamasaki S, Hasegawa H, Okazaki N, Hirohashi S and Kishi K: Angiography of small hepatocellular carcinomas: analysis of 105 resected tumors. AJR Am J Roentgenol 147: 525-529, 1986.
45. Ueda K, Terada T, Nakamura Y and Matsui O: Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study. Hum Pathol 23: 619-626, 1992.
46. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, Popescu A and Popescu I: Expression of p53, BCL- 2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 17: 411-417, 2008.
47. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T and Sugimachi K: Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology 9: 457-460, 1989.
48. Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N and Miura K: Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels. HPB Surg 10: 97-103, 1996.